• Modeling Mechanism：

  Azoxymethane (AOM), a colon-specific procarcinogen, is metabolized and activated in the liver to produce an alkylating intermediate. This intermediate alkylates the DNA of colonic mucosal epithelial cells, inducing gene mutations and initiating tumorigenesis.

• Related Products：

  Azoxymethane (T73719)

• Modeling Method：

  Experimental Subject：

  Rats, Wistar Albino rats, Female, 35 days old

  Dosage and Administration Route：

  ① Core modelling: Intraperitoneal injection of AOM at 7.4 mg/kg at 7 weeks of age;
  ② Control treatment: intraperitoneal injection of equal volume saline solution, with all other housing conditions identical

  Dosing Frequency and Duration Model：

  Single dose

• Validation：

  1. Tumor Characteristics: - Incidence: No significant colorectal tumor formation was observed in the AOM-only treatment group (significant tumors only appear with long-term modeling or combined intervention; single administration mainly targets the tumor initiation stage); - Pathological Basis: Increased epithelial cell proliferation activity was observed in the colonic mucosa, laying the foundation for subsequent tumor progression; 2. Proliferation Indicators: - With prolonged modeling period or combined with other promoting factors, an increase in bromodeoxyuridine (BrdU)-labeled positive cells and increased thymidylate synthase (TS) and thymidine kinase (TK) activities were detected; 3. Molecular Indicators: - DNA alkylation damage-related markers and abnormal expression of oncogenes/tumor suppressor genes were detected in the colonic mucosal tissue.

*Precautions： At the end of the 11th week, the surviving animals were euthanized under ether anesthesia.

*References：Okayasu I,et,al. Promotion of colorectal neoplasia in experimental murine ulcerative colitis. Gut. 1996 Jul;39(1):87-92.